GSK 2798745

Drug Profile

GSK 2798745

Alternative Names: GSK-2798745

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cardiovascular therapies
  • Mechanism of Action TRPV4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure
  • Phase I Pulmonary oedema

Most Recent Events

  • 01 Dec 2016 GlaxoSmithKline completes a phase I trial for Pulmonary oedema in the UK (NCT02119260)
  • 01 Dec 2016 GlaxoSmithKline completes a phase I trial in Heart failure (In volunteers) in USA (PO, Tablet) (NCT02925546)
  • 01 Oct 2016 Phase-I clinical trials in Heart failure (In volunteers) in USA (PO, tablet) (NCT02925546)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top